A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.

Recruiting now · Phase 2/Phase 3

Conditions studied: HCC

In brief

This phase I/II clinical trial aims to determine the efficacy and safety of TATE compared to TACE in patients with intermediate-stage HCC. The results will provide valuable insights into the potential benefits of TATE as a novel treatment option for HCC.

Key facts

Study ID

NCT06844357

Run by

Zhejiang Raygene Pharmaceuticals Co., Ltd

People needed

300

Starts

2025-03-27

Expected to finish

2029-04-01

Last updated by the study team

2025-04-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients diagnosed with primary hepatocellular carcinoma according to AASLD criteria.
• No evidence of extrahepatic metastasis, regional lymph node involvement, or vascular tumor thrombus.
• Patients must be eligible for TAE or TACE treatment.
• ECOG ≤ 1.
• Child-Pugh score ≤ 7.
• Adequate bone marrow, liver, and kidney function is required.

You may not qualify if…

• History of liver transplantation.
• Previous radioemblization or radiotherapy for liver tumors.
• severe cardiovascular or renal diseases, active systemic infections.
• Clinically significant hypoxia (oxygen saturation < 92% without oxygen supplementation)

Where it is running

• Zhongda Hospital, Affiliated to Southeast University — Nanjing, Jiangsu, China (enrolling)
• Lishui Central Hospital — Lishui, Zhejiang, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.